Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (NCT02003222), a randomized phase 3 study. The primary outcome is Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy.

2. Clinical Question

This is a question about a particular subgroup and a time-to-event outcome, not a comparison of every enrolled participant on the primary endpoint. The registry reports 112 participants in each primary-analysis group. It reports a hazard ratio for the comparison, but the median overall-survival estimates themselves are not reported in the registry record. Consequently, the central result is expressed through the relative event-rate comparison and its uncertainty, rather than through a complete set of median survival estimates.

3. Trial Design

The registry describes a randomized phase III trial with parallel groups and no masking. Its title identifies the comparison as combination chemotherapy with or without blinatumomab for newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia in adults. The registry records enrollment of 488 and lists the National Cancer Institute as sponsor. The study began on 2014-05-19, has a recorded primary completion date of 2023-06-23, and has status active, not recruiting.

The two relevant treatment groups are blinatumomab plus chemotherapy and chemotherapy alone. The interventions list blinatumomab, cyclophosphamide, cytarabine, and daunorubicin, along with procedures and biospecimen collection. The specific dosing, sequencing, duration, and eligibility details for each treatment arm are not reported in the registry record. They should not be inferred from the intervention list.

The primary analysis population is defined as all MRD-negative patients randomized to either treatment group after induction and intensification chemotherapy. That definition is narrower than the general trial population. The registry reports 112 participants in each group for this endpoint. The primary outcome is overall survival, measured from randomization to death from any cause. Follow-up assessments are scheduled every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years.

The randomized, parallel design supports a direct comparison of the assigned treatment strategies, but the open-label status means masking was absent. The registry does not report the original sample-size justification, the detailed randomization procedure, or additional allocation safeguards. Those features are therefore not available for judging from the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Induction

Reasons for not completing this period:

Intensification

Reasons for not completing this period:

Randomization/Registration

Maintenance

Analysis population for the primary outcome, as defined in the registry: All MRD-negative patients randomized to either blinatumomab + chemotherapy or chemotherapy alone were included in this analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All patients are included in this analysis.

6. Primary Endpoint

The registry lists the primary outcome as Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy, measured over Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years.

Overall survival is the time from randomization until death from any cause. It is a time-to-event endpoint: each participant contributes information about how long they were followed and whether death was observed during that follow-up. The registry specifies that the primary endpoint applies to patients who were MRD negative after induction and intensification chemotherapy and were randomized to either treatment group.

Overall survival is used because it captures death regardless of the particular cause. This avoids relying on a judgment that a death was specifically related to leukemia or treatment. It is also clinically interpretable as time alive after randomization, although a hazard ratio does not directly state the median time alive or an individual participant’s expected outcome.

The registry lists median overall survival as the endpoint parameter and a 95% confidence interval as its dispersion measure. However, the median estimates are not reported in the registry record. The comparative result available is the sponsor-reported hazard ratio, with its confidence interval and p-value. The listed assessment schedule extends over time, but the registry does not provide the number of deaths, the follow-up distribution, or the details needed to reconstruct the survival curves.

In general, time-to-event methods can use information from participants whose event has not been observed by the end of their follow-up, provided the analysis handles that follow-up appropriately. The registry identifies a log-rank method for the comparison, but fuller details of censoring rules and analytic implementation are not reported in the registry record.

7. Results Posted in the Registry

• MRD Negative - Blinatumomab + Chemotherapy vs MRD Negative - Chemotherapy: hazard ratio 0.44 (95% CI 0.25–0.76), reported p = 0.003 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Relapse-free Survival (RFS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • MRD Negative - Blinatumomab + Chemotherapy vs MRD Negative - Chemotherapy: hazard ratio 0.53 (95% CI 0.31–0.89), reported p = 0.015 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for MRD Negative - Blinatumomab + Chemotherapy vs MRD Negative - Chemotherapy than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

RFS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • MRD+ Then Convert to MRD- vs MRD- Then Remain MRD-: hazard ratio 0.77 (95% CI 0.22–2.65), reported p = 0.670 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between MRD+ Then Convert to MRD- vs MRD- Then Remain MRD- and the control. The interval gives the range of effects that remain compatible with the data.

OS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • MRD+ Then Convert to MRD- vs MRD- Then Remain MRD-: hazard ratio 1.00 (95% CI 0.28–3.63), reported p = 1.000 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between MRD+ Then Convert to MRD- vs MRD- Then Remain MRD- and the control. The interval gives the range of effects that remain compatible with the data.

Across the secondary outcomes, the overall pattern is not a uniform set of precise comparisons. The RFS result in the MRD-negative population is directionally consistent with the primary comparison, while the comparisons based on MRD conversion or remaining MRD negative are less decisive and imprecise. These outcomes address related but different questions, so they should be considered as context rather than as interchangeable replications of the primary endpoint.

The primary result concerns overall survival among MRD-negative patients after induction and intensification chemotherapy. The secondary outcomes include RFS in that population, RFS and OS comparisons between groups defined by subsequent MRD status, and OS among MRD-negative patients proceeding to allogeneic transplant on study. This range of endpoints and populations means the secondary findings do not all estimate the same treatment contrast or apply to the same participants. For the transplant-related outcome, numerical results are not reported in the registry record.

Secondary findings carry less weight when their multiplicity handling and prespecification are not described. Testing several endpoints or subgroups increases the chance that some results will appear notable by chance. The registry does not report a multiplicity adjustment plan or the rationale for choosing the analyses. Accordingly, the secondary outcomes can help describe the broader evidence pattern, but should not be used to amplify the primary finding as if each were a separate confirmatory test.

The record also does not provide all median estimates or confidence intervals for every secondary endpoint. Missing endpoint summaries and limited analysis details further constrain comparisons across outcomes. The primary randomized comparison remains the clearest focus of the posted results; secondary estimates should be interpreted with attention to their distinct populations, uncertainty, and unreported multiplicity strategy.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Relapse-free Survival (RFS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy
• RFS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy
• OS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy
• OS Among MRD Negative Patients Who Proceed to Allogeneic Transplant on Study

9. Statistical Interpretation

10. Statistical Methods Explained

What does the hazard ratio compare?

A hazard ratio compares the event rates over time between two groups, subject to the model and analysis assumptions. For this endpoint, the event is death from any cause. A value below 1 indicates a lower estimated hazard in the first group named in the comparison than in the second. The reported value of 0.44 is therefore interpreted in the direction of blinatumomab plus chemotherapy relative to chemotherapy alone. It is not a ratio of median survival times and should not be translated into an absolute risk difference.

In general, a hazard ratio summarizes relative event rates across follow-up rather than describing a single time point. Its interpretation can be less straightforward if the relative rates change over time. The registry does not report a proportional-hazards assessment or enough information to evaluate that assumption. The reported estimate should therefore be read as the sponsor’s stated summary, not as proof that the relative hazard was constant throughout follow-up.

What does the log-rank method do?

The registry identifies the log-rank method for the primary comparison. In general, the log-rank test compares the observed timing of events between groups over follow-up while accounting for participants who have not had an event by their last recorded assessment. It produces a test of whether the survival experience differs between groups under the method’s assumptions. The registry also reports a hazard ratio and confidence interval, which quantify the estimated direction and precision of the comparison. Details of the estimation procedure, censoring rules, and any supporting model checks are not reported in the registry record.

The test and the effect estimate answer related but distinct questions. A p-value describes how compatible the observed data are with a specified null comparison under the test assumptions. The hazard ratio gives an estimated relative effect, while its confidence interval gives a range of values compatible with the data and method at the stated confidence level. A small p-value alone does not show that an effect is large or important.

Why does the analysis population matter?

The primary endpoint is reported for MRD-negative patients after induction and intensification chemotherapy who were randomized to either group. That defined population matters: the estimate describes the randomized comparison for that subgroup and is not automatically transferable to participants who did not meet the MRD-negative criterion. The registry does not report further detail about the timing or operational definition of MRD assessment, nor does it provide a separate account of missing MRD measurements.

In randomized trials, analysis populations can be defined in different ways, and those choices can affect the interpretation of a treatment comparison. The registry’s primary population description is available, but whether the analysis followed an intention-to-treat principle, how protocol deviations were handled, and how missing outcomes were treated are not reported in the registry record. Those details should not be assumed.

What does a confidence interval add?

A confidence interval expresses uncertainty around an estimate. In general, a narrower interval indicates greater precision and a wider interval indicates less precision, though the interval does not account for every possible source of bias or model error. For the primary hazard ratio, the reported 95% interval ranges from 0.25 to 0.76. It remains below 1, consistent with the direction of the reported comparison, while still allowing a range of relative effects rather than one exact value.

The confidence interval is not a guarantee that the true effect lies within its endpoints. Its usual interpretation depends on repeated use of the same statistical procedure under the relevant assumptions. It also does not provide the probability that any particular effect value is true. The uncertainty represented by the interval should be considered alongside the restricted analysis population and the registry’s missing methodological details.

Why are secondary comparisons harder to interpret?

Secondary outcomes can help explore whether findings extend to other endpoints or patient groups, but multiple comparisons create more opportunities for chance findings. In general, when many hypotheses are tested, interpreting each result as if it were the only test can overstate the strength of evidence. The registry lists four secondary outcomes, but a multiplicity strategy is not reported in the registry record. Secondary p-values should therefore be treated as exploratory unless a prespecified adjustment approach is documented elsewhere in the record.

Some secondary comparisons are restricted to groups defined by MRD status after treatment. Such comparisons address different questions from the primary randomized comparison and may involve selected subsets. The registry reports estimates for those comparisons, but does not report all details needed to assess their analysis populations, missing data, or prespecification. Their results can provide context without replacing the primary endpoint or resolving uncertainty about the study’s analytic plan.

11. Confidence Intervals and Precision

The primary hazard ratio is 0.44, with a 95% confidence interval from 0.25 to 0.76. The interval gives a sense of the precision of the relative-effect estimate: it spans a range of values below 1 rather than concentrating on one exact value. Its direction is consistent with a lower estimated hazard in the blinatumomab-plus-chemotherapy group under the comparison as reported. The interval does not show the absolute survival difference between groups.

The registry does not report the median overall-survival estimates, despite identifying median as the endpoint parameter. It also does not report the number of deaths in the primary-analysis groups, detailed follow-up summaries, or survival estimates at specific times. Those omissions limit interpretation of absolute survival experience and make it impossible to describe the result in terms of median time or a time-specific survival probability from this record.

Precision varies across outcomes. The secondary RFS comparison in the MRD-negative group has a narrower confidence interval than the conditional comparisons involving MRD conversion or remaining MRD negative. Those conditional estimates have broad intervals, indicating substantial uncertainty about the relative effects they represent. A confidence interval that includes 1 is compatible with a range that includes no relative difference under the reported measure, as well as effects in either direction.

Confidence intervals reflect statistical uncertainty under the analysis; they do not automatically include uncertainty from missing data, outcome measurement, deviations from assumptions, or selective reporting. The registry does not provide enough methodological detail to assess all of those issues. Precision should therefore be read as precision within the reported analysis, not as a complete account of every uncertainty about the findings.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size illustrations are planning calculations based on the observed effect, not the original trial design. For these time-to-event comparisons, the entries are total event targets, not participants per arm. The assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each planning scenario targets a stated fraction of the observed effect. The trial’s own original design assumptions and sample-size justification are not reported in the registry record.

The 80% power column describes the event target associated with an 80% chance of detecting the specified effect under the planning assumptions, if that effect and those assumptions were correct. The 90% power column uses a higher chance of detection and therefore generally requires a larger event target. These are planning illustrations; they are not observed power.

The rows that plan for 100% of the observed effect use the full estimated effect as the target. Planning for 75% or 50% of that observed effect asks the calculation to detect a smaller effect. Smaller effects are harder to distinguish from random variation, so the planning calculations require more events and, in practical studies, may require more participants or longer follow-up to accrue those events. The event targets themselves are not participant counts, and the record does not convert them into the number of participants or follow-up duration that would be needed.

Because the illustrations use an effect estimated from the observed results, they should not be mistaken for evidence that the trial was designed around those values. They are conditional planning aids for understanding how assumed effect size and desired power relate to event requirements.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.440, so ln(HR) = -0.8210.
2. d = 4 × (1.96 + 0.842)² / [ln(0.440)]² = 46.6, rounded up to 47 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.44                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(2003222)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 47 (80% power), 63 (90% power)
 75% of observed effect: events = 83 (80% power), 111 (90% power)
 50% of observed effect: events = 187 (80% power), 250 (90% power)
Simulated power with 47 events: 0.759 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Analyses Reported by the Sponsor

The reported primary hazard ratio, confidence interval, and p-value are the sponsor’s analysis as recorded in the registry. The accompanying statistical interpretation uses that reported hazard ratio; it does not replace it with an independently recalculated estimate. The registry record indicates no discrepancy between the reported analysis and the comparison used for this interpretation. Where a discrepancy exists, the sponsor’s own analysis takes precedence; no such discrepancy is flagged for this primary result.

The sponsor identifies the log-rank method and reports the comparison as a superiority analysis. The posted result is a hazard ratio of 0.44 with a 95% confidence interval from 0.25 to 0.76 and p-value 0.003. The estimate is therefore the sponsor’s comparative result, not a fresh calculation from group-level event counts. Group-level event counts and the underlying time-to-event data are not reported in the registry record, so an independent reconstruction of the analysis is not possible from the information listed.

The registry’s median endpoint fields are incomplete for the primary outcome. That does not change the reported hazard ratio, but it limits the additional descriptive interpretation available from this record. The sponsor’s analysis should be read within the primary population definition and the stated outcome, while recognizing that further analysis-plan details are not reported.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and four secondary outcomes. It identifies the primary comparison and reports several secondary analyses, but a multiplicity strategy is not reported in the registry record. In general, when multiple endpoints or subgroup comparisons are examined, the chance of at least one apparently unusual result can increase. Adjustments or a prespecified hierarchy can address that issue, but no such approach should be assumed.

The record does not report whether interim analyses were planned or conducted, whether any stopping rules applied, or how the final analysis timing was determined. It also does not report the full statistical analysis plan. The registry’s status and recorded completion information do not establish what interim procedures were used. These details are important for understanding how the reported tests relate to the full set of analyses, but remain unavailable in this record.

The primary population is explicitly described as MRD-negative patients randomized to either group after induction and intensification chemotherapy. The registry does not state whether all randomized participants were analyzed according to original assignment, how protocol deviations were handled, or how missing MRD assessments and missing outcome data were treated. Censoring criteria and the handling of withdrawals are also not reported in the registry record. These omissions prevent a full assessment of potential missing-data effects or the exact analysis population beyond the description given.

The registry provides an endpoint assessment schedule but not a summary of actual follow-up, the number of events for the primary comparison, or a detailed account of data completeness. It is therefore not possible to judge from the registry record whether follow-up was similar between groups or whether missingness could have influenced the estimates. These are limitations of the available record, not evidence that a particular problem occurred.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutrophil count decreased (92.1%), white blood cell decreased (82.9%), platelet count decreased (80.4%), anemia (50.9%), lymphocyte count decreased (27.8%).

The registry reports serious adverse event figures for several treatment stages or groups, with separate counts at risk and affected. For induction, 479 were at risk and 457 were affected; for intensification, 316 were at risk and 166 were affected. The blinatumomab group lists 146 at risk and 134 affected, while the no-blinatumomab group lists 126 at risk and 121 affected. Maintenance lists 148 at risk and 121 affected. These are registry counts for the named categories and should not be added together, because the record does not establish that they represent mutually exclusive groups.

The most frequently listed serious adverse event terms include neutrophil count decreased at 92.1%, white blood cell decreased at 82.9%, platelet count decreased at 80.4%, anemia at 50.9%, lymphocyte count decreased at 27.8%, and febrile neutropenia at 27.0%. These percentages describe the listed terms in the registry’s safety data; the record does not supply enough detail to infer comparative risks by randomized arm from them.

The registry also lists deaths for these categories, but the counts should not be interpreted as treatment-caused deaths or as a direct comparison of safety between randomized groups. A complete safety interpretation would require consistent exposure periods, event definitions, and arm-specific context. Those details are not reported in the registry record.

17. What the Result Does, and Does Not, Mean

The primary result is a sponsor-reported comparison of overall survival in patients who were MRD negative after induction and intensification chemotherapy. The estimated hazard ratio favors the blinatumomab-plus-chemotherapy group in the direction of the comparison, and its reported confidence interval lies below 1. This is the statistical result described by the registry; it is not a complete account of survival experience or a guarantee of an individual outcome.

The result does not provide an absolute difference in survival probability, a difference in median survival, or a number needed to treat. Median overall-survival values are not reported in the registry record, and the hazard ratio cannot substitute for those quantities. Nor does the subgroup result establish the same effect for participants who were not MRD negative after induction and intensification chemotherapy.

The statistical evidence does not by itself establish clinical importance, explain the mechanism of any difference, or determine the balance of benefit and harm. The registry lists safety information, but its group and phase structure does not provide a complete randomized-arm safety comparison in the record. It would be inappropriate to infer a comprehensive benefit-harm balance from the primary hazard ratio alone.

Interpretation also depends on the trial’s analysis choices and data completeness. The registry does not report the full statistical plan, multiplicity handling, interim-analysis details, censoring rules, or missing-data methods. These absences limit how fully the result can be evaluated, but they do not change the numerical result reported by the sponsor. The appropriate reading is therefore specific: the posted analysis reports a relative overall-survival comparison in a defined MRD-negative randomized subgroup, with uncertainty captured by its confidence interval and with important methodological details unavailable in the registry record.

18. Why This Trial Matters Statistically

This trial is statistically notable because its primary question is a randomized comparison of a time-to-event outcome within a clearly described subgroup. The result is reported as a hazard ratio with a confidence interval and p-value, making it possible to distinguish the estimated relative effect from its precision and statistical compatibility with the null comparison. The subgroup definition is essential: the estimate concerns patients who were MRD negative after induction and intensification chemotherapy, not the whole trial population by default.

The record also illustrates why endpoint summaries matter. Overall survival is listed as a median-time endpoint, yet the median estimates are not reported in the registry record. The hazard ratio supports a relative comparison, but does not convey the absolute survival experience that medians or time-specific estimates might provide. A reader must therefore avoid treating one statistical measure as a substitute for another.

The secondary analyses show why endpoint multiplicity and subgroup selection deserve attention. Several outcomes and MRD-defined populations are listed, but the registry does not report a multiplicity plan or complete analysis details. Their results can add context while remaining less definitive than the primary randomized comparison.

Finally, the planning illustrations clarify the distinction between observed effects and prospective design assumptions. The event targets are conditional calculations based on the observed effect and specified planning assumptions. They do not reveal the trial’s original rationale or establish its achieved power. Together, these features make the record useful for learning how to read a survival comparison while also showing why transparent endpoint summaries and analysis-plan details are important.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record has important trial-specific reporting gaps. Although median overall survival is the primary endpoint parameter, its median estimates are not reported in the registry record. The primary hazard ratio is available, but the record does not include primary-group death counts, detailed follow-up summaries, or survival probabilities at specific times. This limits interpretation of absolute outcomes and prevents a fuller assessment of the survival curves.

The primary analysis is restricted to the MRD-negative randomized subgroup after induction and intensification chemotherapy. The record does not provide enough detail to assess how that status was measured, how missing MRD information was handled, or how the subgroup was defined operationally. The result should not be generalized to other MRD groups without supporting evidence.

Further limitations include the absence of a reported full statistical analysis plan, multiplicity strategy, interim-analysis information, censoring rules, and missing-data methods. The detailed treatment regimens are also not reported in the registry record, so the interventions cannot be reconstructed from the listed drug names alone. The open-label design is stated, but the record does not detail how outcome ascertainment or other procedures addressed the lack of masking.

The safety data are organized by treatment stages and categories, and the record does not establish that these are mutually exclusive populations or provide a complete arm-specific comparison. The registry’s active, not recruiting status and recorded primary completion date do not by themselves supply the missing analysis details or resolve these limitations.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia — NCT02003222.
• Registry record last updated 2026-09-21; status last verified 2026-09.
• Results first posted 2024-09-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT02003222 is a randomized, open-label, parallel-group phase III trial of blinatumomab plus chemotherapy versus chemotherapy alone for adults with newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia. The registry records enrollment of 488 and identifies the National Cancer Institute as sponsor.

The primary endpoint is overall survival among patients who were MRD negative after induction and intensification chemotherapy. The sponsor reports a hazard ratio of 0.44, with a 95% confidence interval from 0.25 to 0.76 and p-value 0.003, for blinatumomab plus chemotherapy versus chemotherapy alone. Median overall-survival estimates are not reported in the registry record.

Secondary outcomes and safety data are also listed, but multiplicity handling, the full analysis plan, and several details about missing data and follow-up are not reported. The posted primary result should be interpreted for its defined subgroup and alongside those reporting limitations.